Immunologic outcome according to donor and conditioning
| Donor . | Conditioning,1st HCT . | No. of patients . | No. of patients surviving >2 y . | No. of patients surviving with . | |||
|---|---|---|---|---|---|---|---|
| CD3+ T cells, >1000/µL . | CD4+ T cells, >600/µL . | Myeloid chimerism . | No IVIG substitution . | ||||
| HLA identical, n = 42 | None | 35 | 30 (85%) | 15 (50%) | 12 (42%) | 6 (20%)* | 21 (56%) |
| cyclo | 4 | 4 | 4 | 3 | 0 | 1 | |
| bu + cyclo | 3 | 3 | 3 | 3 | 2 | 3 | |
| HLA haploidentical, n = 82 | None | 17 | 4† | 3 | 1 | 0 | 0 |
| cyclo or flud | 15 | 4† | 2 | 3 | 0 | 0 | |
| bu + cyclo/flud | 46 | 31 (67%) | 29 (93%) | 26 (83%) | 24 (77%) | 24 (77%) | |
| Other‡ | 4 | 4 | 4 | 4 | 4 | 4 | |
| MUD, n = 8 | None | 1 | 0 | ||||
| bu + cyclo | 7 | 5 | 5 | 3 | 4 | 4 | |
| Other related,§ n = 13 | None | 13 | 6 | 4 | 3 | 1 | 1 |
| Donor . | Conditioning,1st HCT . | No. of patients . | No. of patients surviving >2 y . | No. of patients surviving with . | |||
|---|---|---|---|---|---|---|---|
| CD3+ T cells, >1000/µL . | CD4+ T cells, >600/µL . | Myeloid chimerism . | No IVIG substitution . | ||||
| HLA identical, n = 42 | None | 35 | 30 (85%) | 15 (50%) | 12 (42%) | 6 (20%)* | 21 (56%) |
| cyclo | 4 | 4 | 4 | 3 | 0 | 1 | |
| bu + cyclo | 3 | 3 | 3 | 3 | 2 | 3 | |
| HLA haploidentical, n = 82 | None | 17 | 4† | 3 | 1 | 0 | 0 |
| cyclo or flud | 15 | 4† | 2 | 3 | 0 | 0 | |
| bu + cyclo/flud | 46 | 31 (67%) | 29 (93%) | 26 (83%) | 24 (77%) | 24 (77%) | |
| Other‡ | 4 | 4 | 4 | 4 | 4 | 4 | |
| MUD, n = 8 | None | 1 | 0 | ||||
| bu + cyclo | 7 | 5 | 5 | 3 | 4 | 4 | |
| Other related,§ n = 13 | None | 13 | 6 | 4 | 3 | 1 | 1 |
bu, busulfan; cyclo, cyclophosphamide; flud, fludarabine.
Not evaluated in 4 of 30 patients.
Eighteen patients experienced graft failures after HCT without or with only immunosuppressive conditioning and underwent repeat HCT. Two of 7 survive after immunosuppressive conditioning and 7 of 11 after myelosuppressive conditioning.
Three patients received treosulfan and 1 patient thiotepa instead of busulfan for myelosuppression.
One antigen mismatched, no T-cell depletion.